Skip to content

Return on assets at other companies

Celcuity logo
CelcuityCELC
-61.4%-1.1pp
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-59.4%+270pp
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
12.6%+8.2pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-34.3%+2.7pp
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-13.1%-4.7pp
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-59.7%-8.2pp

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.8B+300%

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0.0×
Current ratio22.1×+2.2×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s return on assets?
Relay Therapeutics, Inc. (RLAY) reported return on assets of -36.4% in Q1 2026.
How has Relay Therapeutics, Inc.'s return on assets changed year-over-year?
Relay Therapeutics, Inc.'s return on assets increased by 10.5% year-over-year, from -40.6% to -36.4%.
What is the long-term trend for Relay Therapeutics, Inc.'s return on assets?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s return on assets has grown at a -2.0% compound annual growth rate (CAGR), from -40.2% to -37%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.